Expertise in
22
conditions

Dr. William E. Gillanders

Surgical Oncology | General Surgery
Washington University
4921 Parkview Pl, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
22
conditions
Washington University
4921 Parkview Pl, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Gillanders is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Gillanders is highly rated in 22 conditions, according to our data. His top areas of expertise are Breast Cancer, Hyperparathyroidism, Thyroid Cancer, Parathyroidectomy, and Thyroidectomy. Dr. Gillanders is currently accepting new patients.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Surgical Oncology
General Surgery
Licenses
Surgery in MO
Hospital Affiliations
Alton Memorial Hospital
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Memorial Hospital
Missouri Baptist Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

WASHINGTON UNIVERSITY
4921 Parkview Pl, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer
Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer
Enrollment Status: Recruiting
Publish Date: April 23, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Durvalumab, Gemcitabine Hydrochloride, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Tremelimumab
Study Phase: Phase 2
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer
Enrollment Status: Recruiting
Publish Date: March 01, 2024
Intervention Type: Drug, Procedure, Device
Study Drug: LS301
Study Phase: Phase 1/Phase 2
Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Biological, Drug, Device, Procedure
Study Drugs: Neoantigen DNA Vaccine, Durvalumab
Study Phase: Phase 2
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Biological
Study Drugs: Optimized Neoantigen Synthetic Long Peptide Vaccine, Poly-ICLC
Study Phase: Phase 1
A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Biological, Procedure
Study Drug: Mammaglobin-A DNA Vaccine
Study Phase: Phase 1
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Device, Biological, Drug
Study Drugs: Personalized neoantigen DNA vaccine, Plasmid encoded IL-12
Study Phase: Phase 1
Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)
Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Procedure, Drug
Study Drugs: carboplatin, paclitaxel, atezolizumab
Study Phase: Phase 2
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Enrollment Status: Terminated
Publish Date: July 17, 2024
Intervention Type: Drug, Biological, Procedure
Study Drugs: Poly-ICLC, CD4/CD8-Positive Personalized Neoantigen Peptide Vaccine
Study Phase: Phase 1
A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Enrollment Status: Terminated
Publish Date: May 28, 2024
Intervention Type: Device, Biological, Drug, Procedure
Study Drugs: Durvalumab, Neoantigen DNA vaccine
Study Phase: Phase 1
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen DNA Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen DNA Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Enrollment Status: Terminated
Publish Date: October 10, 2023
Intervention Type: Biological, Procedure, Device
Study Drug: Personalized Neoantigen DNA Vaccine
Study Phase: Phase 1
Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: August 14, 2023
Intervention Type: Procedure, Drug, Biological
Study Drugs: Personalized tumor vaccine, Poly ICLC, Nivolumab, Rituximab
Study Phase: Phase 1
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Drug, Procedure
Study Drugs: Docetaxel, Carboplatin
Study Phase: Phase 2
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
Enrollment Status: Terminated
Publish Date: November 01, 2022
Intervention Type: Drug, Biological
Study Drugs: Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil
Study Phase: Phase 2
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Terminated
Publish Date: October 27, 2021
Intervention Type: Procedure, Biological
Study Phase: Phase 1
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
Enrollment Status: Withdrawn
Publish Date: May 25, 2021
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 1
A Randomized Phase II PIVOT-RCC (PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma) Trial
A Randomized Phase II PIVOT-RCC (PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma) Trial
Enrollment Status: Withdrawn
Publish Date: August 13, 2020
Intervention Type: Procedure, Device, Drug, Biological
Study Phase: Phase 2
Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial
Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: June 25, 2020
Intervention Type: Device, Behavioral, Procedure, Other
Study Phase: Phase 2
Pilot Feasibility Study of the Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Pilot Feasibility Study of the Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: April 12, 2019
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 1
A Prospective Randomized Trial of Sentinel Lymph Node Biopsy Versus no Additional Staging in Patients With Clinical T1-T2 N0 M0 Invasive Breast Cancer and Negative Axillary Ultrasound
A Prospective Randomized Trial of Sentinel Lymph Node Biopsy Versus no Additional Staging in Patients With Clinical T1-T2 N0 M0 Invasive Breast Cancer and Negative Axillary Ultrasound
Enrollment Status: Terminated
Publish Date: March 05, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: November 17, 2017
Intervention Type: Drug, Biological
Study Phase: Phase 1
View 18 Less Clinical Trials

95 Total Publications

Discussion: Breast Implants Elicit Local and Systemic Immune Response: Evidence for Breast Cancer Immunosurveillance.
Discussion: Breast Implants Elicit Local and Systemic Immune Response: Evidence for Breast Cancer Immunosurveillance.
Journal: Plastic and reconstructive surgery
Published: April 28, 2025
Similar Doctors
Expertise in
58
conditions
Dr. Ryan C. Fields
Surgical Oncology | General Surgery | Emergency Medicine
Expertise in
58
conditions
Dr. Ryan C. Fields
Surgical Oncology | General Surgery | Emergency Medicine

Washington University

216 S Kingshighway Blvd, 
Saint Louis, MO 
 (0.1 mi)
314-362-9355
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ryan Fields is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Fields is highly rated in 58 conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Cancer, Gallbladder Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Fields is currently accepting new patients.

Expertise in
18
conditions
Dr. Julie A. Margenthaler
Surgical Oncology | General Surgery
Expertise in
18
conditions
Dr. Julie A. Margenthaler
Surgical Oncology | General Surgery

Washington University

12634 Olive Blvd, 
Saint Louis, MO 
 (11.3 mi)
314-542-9378
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Julie Margenthaler is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Margenthaler is highly rated in 18 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Intraductal Papilloma, Mastectomy, and Lymphadenectomy. Dr. Margenthaler is currently accepting new patients.

Expertise in
19
conditions
Dr. Rebecca L. Aft
Surgical Oncology | General Surgery
Expertise in
19
conditions
Dr. Rebecca L. Aft
Surgical Oncology | General Surgery

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 mi)
314-362-4699
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rebecca Aft is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Aft is highly rated in 19 conditions, according to our data. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, Mastectomy, and Lymphadenectomy. Dr. Aft is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gillanders's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 7 Advanced Conditions
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile